GVS Acquires Haemonetics' Transfusion Business in $67M Deal
Deal News | Dec 03, 2024 | Finance Community IT - 1 Corporate M&A
GVS, a company listed on Euronext Milan and known for its filtration solutions across Healthcare & Life Sciences, Energy & Mobility, and Health & Safety sectors, has successfully acquired the transfusion medicine business from Haemonetics. Haemonetics, a U.S.-listed company, will transfer its whole blood division to GVS for a total consideration of $67 million. This strategic acquisition is aimed at enhancing GVS's competitive edge in the transfusion medicine sector by offering a vertically integrated product line, expanding its geographical reach, and advancing into the B2C market. The acquisition was facilitated by Sella Investment Banking, with its M&A Advisory team, led by Francesco Falcone, acting as GVS's exclusive financial advisor. Sella Investment Banking guided GVS through structuring the acquisition, coordinating due diligence, and handling negotiation processes. The move is part of GVS's broader strategy to strengthen its market presence globally. The company, headquartered in Zola Pedrosa, Bologna, operates 19 plants and 29 sales offices worldwide, reporting revenues of €425 million and an EBITDA of €95 million in 2023.
Sectors
- Healthcare & Life Sciences
- Investment Banking & Advisory
- Manufacturing
Geography
- Italy – GVS is headquartered in Zola Pedrosa, Bologna, Italy, and is listed on Euronext Milan.
- United States – Haemonetics, the company selling its transfusion business, is listed in the United States.
Industry
- Healthcare & Life Sciences – GVS operates in the Healthcare & Life Sciences sector, providing filtration solutions for transfusion medicine.
- Investment Banking & Advisory – Sella Investment Banking provided financial advisory services for the acquisition.
- Manufacturing – GVS manufactures filtration solutions and operates multiple manufacturing plants globally.
Financials
- 67,000,000 USD – The total consideration for the acquisition of Haemonetics' transfusion business by GVS.
- 425,000,000 EUR – GVS's reported revenues for 2023.
- 95,000,000 EUR – GVS's EBITDA for 2023.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| GVS | Acquirer | Company | A publicly traded company on Euronext Milan, specializing in filtration solutions. |
| Haemonetics | Target Company | Company | A U.S.-listed company providing blood management solutions. |
| Sella Investment Banking | Financial Advisor | Company | Provided exclusive financial advisory services to GVS for the acquisition deal. |
| Francesco Falcone | Head of M&A Advisory | Person | Led the advisory team at Sella Investment Banking for the GVS acquisition. |